Morepen Laboratories share news, announcements and annual reports
NSE: MOREPENLABBSE: 500288Pharmaceuticals & BiotechnologySmall Cap
Morepen Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 1993 on BSE, Nov 1999 on NSE
Last close ₹119.31down ₹6.27 (4.99%)BSE ₹119.65
Share price at the NSE close on 29 Oct 2026. Previous close ₹125.58.
29 Oct: open ₹119.31, high ₹119.31, low ₹119.31
52-week range of traded prices to 29 Oct 2026
₹33.05Low, 30 Mar 2026₹150.70High, 7 Oct 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6,538 Cr1,108th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.67
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.73
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.17%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 14.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.22
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 9,00,028
Morepen Laboratories share news and announcements
606 announcements, routine notices left out, newest first. Page 13 of 13.
Apr 2007
2 Apr · Investment/Others
In furtherance to the implementation of the CDR package the Board of Directors in its meeting held on March 31, 2007 has revisited in detail the investment proposals and reviewed the compliances made in this regard. The following decisions were taken in the Board meeting. (1) The investment proposal of Avenue Asia Fund, in view of the need to adhere to the timelines drawn, not to be proceeded with; (2) The Board approved the issuance of upto 2,44,90,000 Equity Shares and 5,36, 50,000 Warrants with rights attached to subscribe to Equity shares, to new Investors, existing bankers/Financial Institutions and Promoters at a price of Rs.20/- only which is a price based on SEBI formula, subject to the shareholders approval. (3) The Shareholders approval be sought by convening the Extra Ordinary General Meeting.
Mar 2007
20 Mar · Limited Review Report
Auditor's have conducted the limited review of the unaudited financial results for the quarter ended December 31, 2006 and found the same to be in order subject to certain observations. The auditor's observations are : subject to the non provision of interest on loans (public deposits) for the quarter amounting to Rs. 282.21 lacs as a result the figure of loss for the quarter is under stated by Rs. 282.21 lacs.16 Mar · Board meeting
In furtherance to implementation of CDR package, the Board of Directors in its meeting, held on March 15, 2007, has approved the following investment in the company for settlement of Debts, Capital expenditure and working capital : (1) Issuance of Equity Share Capital amounting to Rs.150 Crore (14.99% of the Equity Capital) to Avenue Asia Fund and raising Rs.100 Crore by way of debt from an International Bank (New Investors); (2) Issuance of Warrants with right to subscribe to equity shares (upto 10% of Equity Capital) to new Investors; (3) Issuance of Equity Share Capital of upto Rs. 17 Crore to existing banks / Financial Institutions as part of settlement package; and (4) Issuance of 0.01% Optionally Convertible Preference shares amounting to Rs.90 Crore to Banks/Financial Institutions / existing preference shareholders as part of settlement package8 Mar · Board meeting
Convening the Board Meeting on 15.03.2007 to consider issuance of Equity Shares/Securities/Warrants to Investors, Banks and Financial Institutions on Preferential allotment basis. Further the Company has informed the Exchange that this matter would be considered by the Board, pursuant to the CDR package approved by the Lenders.
Feb 2007
21 Feb · Management
Mr. Darpan Batra, designated as Asst. Company Secretary, has been appointed as Compliance Officer of the company with effect from February 19, 2007
Jan 2007
25 Jan · Board meeting
Meeting on 31 Jan 2007: “Unaudited Financial Results for the quarter ended Dec 31, 06”